U.S. Grants Final Approval to Novavax COVID-19 Vaccine Amid Delays and New Restrictions
The U.S. has officially approved Novavax's COVID-19 vaccine Nuvaxovid, with new restrictions limiting its use to certain high-risk groups, following a delayed approval process.
In a significant development, U.S. health regulators have officially approved Novavax's COVID-19 vaccine, Nuvaxovid, after an unexpected delay. The approval comes with new restrictions on the vaccine's use, raising discussions within the medical community. Novavax sought full approval from the Food and Drug Administration (FDA), having previously received emergency use authorization for individuals aged 12 and older. Unlike mRNA vaccines from Pfizer-BioNTech and Moderna, Nuvaxovid employs different technology and had not yet achieved full approval.
The FDA initially aimed to finalize the approval process by April 1 but missed this deadline, stirring concerns about regulatory reforms under former President Donald Trump and his then-Health Secretary, which critics argue impacted the approval process. The newly approved vaccine is now authorized only for specific groups: those aged 65 and above, and individuals aged 12 to 64 with underlying health conditions such as obesity or asthma that increase COVID-19 risk.
These restrictions have prompted scrutiny, especially as vaccine skepticism remains a topic of debate. Notably, vaccine skeptics like Robert F. Kennedy Jr. have criticized regulatory decisions and promoted misinformation about vaccines, including those administered to children. His influence and skepticism have gained attention amid recent measles outbreaks, prompting renewed conversations about vaccine governance.
While the approval marks an important milestone for Novavax, the limited authorization underscores ongoing debates over vaccine safety, regulation, and public health policies. The decision emphasizes targeted use of the vaccine, focusing on vulnerable populations, amid a complex landscape of COVID-19 vaccination efforts.
[Source: https://medicalxpress.com/news/2025-05-novavax-covid-jab-delay-restrictions.html]
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Emerging Role of Immunotherapy for Organ Transplant Patients with Advanced Cancer
New research reveals that carefully managed immunotherapy can benefit organ transplant recipients with advanced cancer, offering promising survival outcomes despite some rejection risks.
The Role of Education and Social Factors in Rheumatic and Musculoskeletal Diseases
Emerging research emphasizes the critical role of social determinants like income and education in shaping outcomes for patients with rheumatic and musculoskeletal diseases. Findings from the EULAR 2025 congress reveal how these factors influence disease progression and mortality, highlighting the need for targeted interventions to promote health equity.
New Research Model Sheds Light on the Vesicle Cycle and Brain Synapse Function
Recent scientific advances have led to a highly detailed computational model of the vesicle cycle in synapses, providing new insights into how neurons communicate and supporting neurological research and treatments.